Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2013 Dec 1;19(23):6566-77. doi: 10.1158/1078-0432.CCR-13-1511. Epub 2013 Sep 19.

End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis.

Author information

1
Authors' Affiliations: Center for Evaluation Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Departments of Imaging and Medical Oncology, Dana-Farber Cancer Institute; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Abstract

PURPOSE:

Use of 2[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in postchemotherapy response assessment in follicular lymphoma is still a controversial issue. Here, we conducted the first systematic review and meta-analysis to determine the predictive value of FDG-PET in predicting outcome after chemotherapy of follicular lymphoma.

EXPERIMENTAL DESIGN:

Comprehensive literature search in Ovid-MEDLINE and EMBASE databases was performed to identify studies which evaluate predictive value of end-therapy PET and/or computed tomography (CT) in patients with follicular lymphoma. To quantitatively compare the predictive value of PET and CT, pooled hazard ratios (HRs) comparing progression-free survival (PFS) between patients with positive and negative results were adopted as the primary indicators for meta-analysis. To explore the efficiency in determining complete remission (CR), pooled CR rates of PET- and CT-based response criteria were calculated. Pooling of these parameters was based on the random-effects model.

RESULTS:

Review of 285 candidate articles identified eight eligible articles with a total of 577 patients for qualitative review and meta-analysis. The pooled HRs of end-therapy PET and CT were 5.1 [95% confidence interval (CI), 3.7-7.2] and 2.6 (95% CI, 1.2-5.8), respectively, which implies that PET is more predictive of PFS after chemotherapy than CT. The pooled CR rates of PET- and CT-based response criteria were 75% (95% CI, 70-79%) and 63% (95% CI, 53-73%), respectively, which implies that PET is more efficient in distinguishing CR (without residual disease) from other states with residual disease. In addition, qualitative systematic review indicates the same findings.

CONCLUSIONS:

Consistent evidence favoring PET-based treatment assessment should be considered in the management of patients with follicular lymphoma.

PMID:
24052020
DOI:
10.1158/1078-0432.CCR-13-1511
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center